Welcome to our dedicated page for Affimed news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed stock.
Affimed N.V. (AFMD) has been a Nasdaq-listed, clinical-stage immuno-oncology company focused on innate cell engagers (ICE®) generated on its proprietary ROCK® platform. Company news has highlighted how these ICE® molecules are being developed to recognize and kill a range of hematologic and solid tumors by engaging innate immune cells.
News coverage for AFMD includes detailed clinical updates on key ICE® programs such as AFM24, AFM28 and acimtamig (AFM13). Releases describe AFM24 as a tetravalent, bispecific ICE® targeting CD16A and EGFR, with data in advanced or metastatic non-small cell lung cancer, including combinations with atezolizumab. For AFM28, Affimed has reported early Phase 1 results in relapsed/refractory acute myeloid leukemia, including composite complete remission rates and safety findings. Additional news has covered acimtamig in combination with AlloNK® (AB-101) in classical Hodgkin lymphoma, with abstracts accepted for major oncology meetings.
Another important category of AFMD news relates to corporate and listing developments. In May 2025, Affimed announced that it had filed for insolvency proceedings in Mannheim, Germany, citing overindebtedness and liquidity concerns. Shortly thereafter, the company disclosed that Nasdaq staff would suspend trading of its common shares and proceed with a delisting process, culminating in a Form 25 filing to remove its common stock from Nasdaq listing and registration.
On this news page, readers can review historical press releases on AFMD’s clinical trial data, conference presentations, investor webcasts, and regulatory and listing updates. For those tracking the company’s ICE® pipeline and its insolvency and delisting process, this archive offers a centralized view of how Affimed’s scientific, clinical, and corporate story has evolved over time.
Heidelberg, Germany, October 14, 2020 – Affimed N.V. (Nasdaq: AFMD) announced the presentation of preclinical data at the upcoming SITC Annual Meeting from its collaboration with MD Anderson Cancer Center and Washington University. The oral presentation is titled AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies and will occur on November 11, 2020. AFM13, a bispecific innate cell engager, targets CD30-positive tumor cells and is actively being tested in a registration-directed trial for relapsed/refractory peripheral T-cell lymphoma.
Affimed N.V. (Nasdaq: AFMD) announced the first dosing of a patient in a groundbreaking clinical study that combines cord blood-derived natural killer (cbNK) cells with AFM13. This innovative trial focuses on patients with recurrent or refractory CD30-positive lymphomas. The study aims to evaluate both the safety and efficacy of this first-in-class treatment, utilizing preloaded NK cells to enhance the immune response against tumors. The trial expects to enroll about 30 patients at MD Anderson Cancer Center, marking a significant step in immuno-oncology.
AbCheck announced a grant from the Ministry of Industry and Trade of the Czech Republic, valued at up to €1.44 million over the next 3 years. This funding supports the development of a microfluidic system for discovering rare therapeutic antibodies. The innovative technology allows screening millions of droplets containing antibody-expressing cells daily, enhancing the discovery of functional antibodies critical for cancer treatments. The grant will expedite the creation of specialized bioassays, reinforcing AbCheck's commitment to advanced antibody discovery.
Heidelberg, Germany, September 29, 2020 – Affimed N.V. (Nasdaq: AFMD) announced its presentation at the Jefferies Virtual Cell Therapy Conference on October 6 at 8:00 a.m. Eastern Time. The event's live webcast will be accessible via the “Investors” section on Affimed’s website and will remain available for 30 days post-event. Affimed focuses on innovative immuno-oncology treatments, leveraging its ROCK® platform for tailored therapies aimed at hematologic and solid tumors. The company is currently advancing studies on AFM13 and AFM24.
Heidelberg, Germany, September 2, 2020 – Affimed N.V. (Nasdaq: AFMD) announced its participation in several investor conferences throughout September 2020. These include:
- Wells Fargo Virtual Healthcare Conference on September 9, 2020, featuring a fireside chat at 8:00 a.m. ET.
- Citi’s 15th Annual BioPharma Virtual Conference on September 10, 2020.
- Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020, at 12:40 p.m. ET.
- Oppenheimer Fall Healthcare Life Sciences Summit on September 21, 2020, at 3:20 p.m. ET.
Affimed N.V. (Nasdaq: AFMD) announced its Q2 2020 financial results, reporting revenue of €2.9 million, down from €4.0 million in Q2 2019. The company has €92.6 million in cash, projected to support operations into H1 2022. The AFM13 study has activated 54 sites across 10 countries, with interim analysis expected mid-2021. Additionally, AFM24 is advancing in Phase 1/2a trials, and the collaboration with Genentech has achieved a milestone triggering a payment. Despite a net loss of €12.2 million, the management team is optimistic about ongoing projects and future developments.
Affimed N.V. (Nasdaq: AFMD) has appointed Dr. Annalisa Jenkins and Mr. Harry Welten to its Supervisory Board, effective from August 4, 2020. Dr. Jenkins brings over 25 years of pharmaceutical experience, having held leadership roles at companies like Merck Serono and Bristol-Myers Squibb, while Mr. Welten offers extensive financial and U.S. market expertise from his roles in various biotech firms. These appointments aim to enhance corporate governance and strengthen the company's strategic positioning in the biotech industry.
Affimed N.V. (Nasdaq: AFMD) will hold its Annual General Meeting of Shareholders on August 4, 2020, at the Sheraton Amsterdam Airport Hotel, starting at 11:00 a.m. CET. The meeting's notice and agenda can be found on Affimed’s Investor Relations page and the SEC website. The company is focused on developing therapies for cancer, using its ROCK® platform for patient-specific treatments. Current studies include AFM13 for CD30-positive peripheral T cell lymphoma and AFM24 for advanced EGFR-expressing solid tumors.
Affimed N.V. (Nasdaq: AFMD) announced progress in its clinical trials, completing the first dose cohort of its Phase 1/2A study for AFM24, with recruitment for cohort 2 now open. Financial results for Q1 2020 showed total revenue of €5.1 million, down from €11.4 million year-over-year, and a net loss of €8.3 million. Cash and equivalents stood at €88.2 million as of March 31, 2020, with expectations to fund operations into the first half of 2022. Key management appointments completed with Angus Smith as CFO, enhancing the leadership team.
Affimed N.V. (Nasdaq: AFMD) showcased promising data on its Innate Cell Engagers (ICE) at the AACR Virtual Annual Meeting II. The research highlighted the effectiveness of AFM24 and Genentech’s RO7297089 in preclinical models, targeting tumor cells with low expression. Both agents demonstrated significant tumor cell killing via dual mechanisms, activating innate immune systems while maintaining favorable safety profiles in cynomolgus monkeys. AFM24 is currently progressing into further clinical studies, suggesting potential for broader application in treating EGFR-positive tumors.
FAQ
What is the current stock price of Affimed (AFMD)?
What is the market cap of Affimed (AFMD)?
